New hope for advanced cancer: experimental drug combo enters human testing
NCT ID NCT04855656
First seen Jan 23, 2026 · Last updated May 05, 2026 · Updated 8 times
Summary
This early-phase study tests an experimental drug called lunresertib, given alone or with other drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. About 464 adults and children aged 12 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
# 1019, UCLA, Westwood Cancer Center
COMPLETEDLos Angeles, California, 90095, United States
-
#1001, The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
#1002, Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
#1004, Memorial Sloan Kettering Cancer Institute
RECRUITINGNew York, New York, 10065, United States
-
#1007, Rhode Island Hospital
RECRUITINGProvidence, Rhode Island, 02903, United States
-
#1008, Columbia University
COMPLETEDNew York, New York, 10032, United States
-
#1010, University of Pennsylvania
COMPLETEDPhiladelphia, Pennsylvania, 19104, United States
-
#1011, Washington University
RECRUITINGSt Louis, Missouri, 63130, United States
-
#1012, Yale
RECRUITINGNew Haven, Connecticut, 06520, United States
-
#1013, The University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
#1016, Mayo Clinic
RECRUITINGRochester, Minnesota, 55902, United States
-
#1017, Mayo Clinic
RECRUITINGJacksonville, Florida, 32224, United States
-
#1023, START Midwest
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
#1025, University of California San Francisco
RECRUITINGSan Francisco, California, 94158, United States
-
#1027, University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
-
#1030, Women & Infants Hospital of Rhode Island
RECRUITINGProvidence, Rhode Island, 02903, United States
-
#1032, Northwell Health Cancer Institute
RECRUITINGNew Hyde Park, New York, 11042, United States
-
#2001, Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2C1, Canada
-
#2002, The Hospital for Sick Children
COMPLETEDToronto, Ontario, M5G 1X8, Canada
-
#2003, The Research Institute of the McGill University Health Centre
COMPLETEDMontreal, Quebec, H4A 3J1, Canada
-
#3003, Sarah Cannon Research Institute
RECRUITINGLondon, W1G 6AD, United Kingdom
-
#4001, Rigshospitalet - Blegdamsvej
RECRUITINGCopenhagen, Denmark
Conditions
Explore the condition pages connected to this study.